top of page
PIPELINE & RESEARCH PRIORITIES

From one advanced program to a focused multimodal pipeline.

Our strategy starts with LUT001 (formerly PXT3003) in CMT1A and extends to next-generation combination therapies for CMT1A, ALS and Alzheimer’s disease.

One lead program. Three research priorities.

LEAD PROGRAM

LUT001 — CMT1A

Phase 3 development history · Next development strategy

An investigational fixed-dose oral combination of baclofen, naltrexone and D-sorbitol. LUT001 anchors Lutetia’s development strategy in CMT1A, supported by an extensive clinical record spanning Phase 2, Phase 3 studies and long-term follow-up.

RESEARCH / NEXT-GENERATION PRIORITIES

Next-generation CMT1A

Research planning

Explore next-generation combinations incorporating novel components that could build on the LUT001 approach.

LUT002 — ALS

Research planning

Investigate combination strategies addressing complementary mechanisms in amyotrophic lateral sclerosis.

LUT003 — Alzheimer’s disease

Research planning

Explore rational combinations addressing complementary mechanisms in Alzheimer’s disease.

LUT001 is the foundation. CMT1A Gen2, ALS and Alzheimer’s are where Lutetia is building next.

THE HUMAN NEED

Three diseases. Significant unmet need.

CMT1A

1–5

per 10,000

CMT1A-specific prevalence.

Disease-burden figures use different populations and geographies and are presented for context only; they are not estimates of treatable or commercially addressable populations.

ALS

34,720

Adults in U.S.

Projected adults aged 18 and older living with ALS in the United States in 2026.

Alzheimer’s disease

7.4 million

Estimated U.S. adults

Estimated U.S. adults aged 65 and older living with clinical Alzheimer’s dementia in 2026.

A TWO-GENERATION STRATEGY

Established components. Next-generation combinations.

Generation 1

Combination concepts based primarily on approved or otherwise well-characterized active ingredients.

Generation 2

Combination concepts incorporating at least one new chemical entity or other novel therapeutic component.

The ALS and Alzheimer’s research priorities encompass both concepts; next-generation CMT1A focuses on Gen2.

STRATEGIC DISCOVERY COLLABORATION

Discovery meets development.

Lutetia     ×     Tangramed

In September 2026, Lutetia and Tangramed signed a framework term sheet for a discovery collaboration across next-generation CMT1A, ALS and Alzheimer’s disease.

Tangramed — Discover & Validate

Lutetia — Develop & Execute

Tangramed would contribute combination design and biological evaluation through its Integral Therapy Design approach, drawing on PleoBotâ„¢ and Patient Avatar Cohort (PAC). Tangramed retains ownership of these discovery technologies.

For products subsequently selected and licensed under definitive agreements, Lutetia would lead clinical development, regulatory work, CMC and manufacturing, commercialization and partnering.

CMC: Chemistry, Manufacturing and Controls.

Design → Validate → Develop

Product development follows subsequent selection and licensing.

Tangramed

Help shape the next generation.

We welcome conversations with investors, biopharma partners and scientific collaborators who share our ambition for multimodal therapies in neurology.

bottom of page